Literature DB >> 9099934

Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10.

T Kucharzik1, N Lügering, H Weigelt, M Adolf, W Domschke, R Stoll.   

Abstract

Activated monocytes with increased expression of proinflammatory cytokines play a major role in inflammatory bowel disease (IBD). Immunoregulatory cytokines such as IL-4 and IL-10 can effectively suppress the proinflammatory response of activated monocytes. IL-13 is a recently described antiinflammatory agent in vitro. The aim of our study was to determine the in vitro immunosuppressive capacity of IL-13, IL-4 and IL-10 in patients with IBD. Peripheral blood monocytes were isolated from 27 patients with ulcerative colitis (UC), 27 patients with Crohn's disease (CD) and 16 healthy controls. Cells were stimulated with pokeweed mitogen (PWM) after treatment with IL-13, IL-4 and IL-10, and secretion of IL-1beta, tumour necrosis factor-alpha (TNF-alpha) and IL-6 was assessed using sandwich ELISA systems. Peripheral blood monocytes secreted significantly increased amounts of TNF-alpha and IL-6 under stimulation with PWM in patients with CD, while UC patients showed significantly elevated levels of IL-1beta. The antiinflammatory cytokines IL-13, IL-4 and IL-10 were all capable of inhibiting monocyte secretion of IL-1beta in a dose-dependent manner. With regard to IL-13 and IL-4, there was no significant suppression of TNF-alpha and IL-6 in patients with active IBD. By contrast, IL-10 was able to down-regulate all proinflammatory cytokines in active IBD as well as in controls. Proinflammatory cytokines from patients with inactive IBD could be significantly down-regulated by all three immunoregulatory cytokines. The inhibitory effect of IL-13 on TNF-alpha and IL-6 production in differentiated macrophages was diminished in IBD patients, as well as in controls. In disease controls we also observed a reduced inhibition of TNF-alpha and IL-6 after treatment with IL-13. In conclusion, the antiinflammatory activity of IL-13 is partially reduced in patients with active IBD. The hyporesponsiveness of activated and differentiated monocytes to IL-13 and IL-4 does not seem to be a disease-specific phenomenon.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9099934      PMCID: PMC2200460          DOI: 10.1046/j.1365-2249.1996.39750.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Distinctive pattern of cytokine production and adhesion molecule expression in peripheral blood memory CD4+ T cells from patients with active Crohn's disease.

Authors:  Jaime García de Tena; Luis Manzano; Juan Carlos Leal; Esther San Antonio; Verónica Sualdea; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

3.  IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease.

Authors:  N Lügering; T Kucharzik; H Stein; G Winde; A Lügering; A Hasilik; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

4.  Importance of combined treatment with IL-10 and IL-4, but not IL-13, for inhibition of monocyte release of the Ca(2+)-binding protein MRP8/14.

Authors:  N Lügering; T Kucharzik; A Lügering; G Winde; C Sorg; W Domschke; R Stoll
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

5.  Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease.

Authors:  T Kucharzik; N Lügering; M Adolf; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

6.  Therapeutic effects of four strains of probiotics on experimental colitis in mice.

Authors:  Lin Lin Chen; Xue Hong Wang; Yi Cui; Guang Hui Lian; Jie Zhang; Chun Hui Ouyang; Fang Gen Lu
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

7.  Identification of immunological parameters associated with the alveolar bone level in periodontal patients.

Authors:  Chang-Seo Park; Ju-Yeon Lee; Sung-Jo Kim; Jeom-Il Choi
Journal:  J Periodontal Implant Sci       Date:  2010-04-15       Impact factor: 2.614

8.  Aberrant activation of nuclear factor of activated T cell 2 in lamina propria mononuclear cells in ulcerative colitis.

Authors:  Tsung-Chieh Shih; Sen-Yung Hsieh; Yi-Yueh Hsieh; Tse-Chin Chen; Chien-Yu Yeh; Chun-Jung Lin; Deng-Yn Lin; Cheng-Tang Chiu
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells.

Authors:  G Bisping; N Lügering; S Lütke-Brintrup; H G Pauels; G Schürmann; W Domschke; T Kucharzik
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

10.  Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10.

Authors:  T Kucharzik; N Lügering; G Winde; W Domschke; R Stoll
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.